By Rob Rittberg, Global Marketing Manager - Clinical Informatics
Risk-Based Monitoring has been a glacial paradigm, slowly moving through the industry with deep insights hidden below the water line. It might be interesting to know that it first appeared almost 20 years ago. And, the promise of #RBM has always been consistent: to increase efficiency, subject safety, trial efficacy while lowering operational (monitoring) costs.
There are competing metrics on the actual adoption rate of RBM in the industry. Metrics Champion Consortium indicated the use of RBM across the industry at 27% in 2011 growing to 52% in 2013 and 75% in 2015. Extrapolating that trend, we should easily be at 90% adoption now. That’s just not the case. While there is an excess of information on RBM, accurate adoption rates and a clear and consistent way forward based on proven results is still in formulation.